SynAffix is a protein engineering company focusing on technology development for next-generation, site-specific, antibody-drug conjugates (ADCs) for the treatment of cancer and other diseases. The company’s proprietary GlycoConnectTM technology, comprising precision modification of a protein's native glycosylation site, allows for fast construction of stable and homogeneous ADCs. Synaffix is based in Oss, The Netherlands.